Clinically, AKI has long been considered a hypercatabolic state, which adversely affects outcomes, including mortality 13,14
In June 2026 the MHRA approved oral semaglutide, marketed as the Wegovy pill , the first oral GLP-1 receptor agonist licensed in the UK for weight management (distinct from Rybelsus, a lower-dose oral semaglutide licensed for type 2 diabetes)
This means that it is critical for the delivery of fat and the conversion of said fat into energy
According to research, the average person loses about 15% to 20% of their total body weight
As a potent bioflavonoid, quercetin supports the immune system in a dose-dependent manner
is supported by the Mary Pack Chair in Rheumatology Research from the University of British Columbia and The Arthritis Society of Canada